trending Market Intelligence /marketintelligence/en/news-insights/trending/nyaVLHSKz8WFUE9cx-dA7A2 content esgSubNav
In This List

Coherus, Daiichi Sankyo end Enbrel biosimilar license deal

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet

Blog

Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback

Infographic

Infographic: The Big Picture 2023 Sustainability Outlook

Blog

The Big Picture for 2023: Assessing Investment Trends and the Impact of Investor Activism


Coherus, Daiichi Sankyo end Enbrel biosimilar license deal

Coherus Biosciences Inc. and Daiichi Sankyo Co. Ltd. terminated their contract regarding Coherus' Enbrel biosimilar product candidate CHS-0214.

The contract termination is due to Daiichi Sankyo's recent decision to discontinue development of CHS-0214 in Japan.

Coherus will not incur any early termination penalties.

Amgen Inc.'s Enbrel, or etanercept, is used to treat patients with moderately to severely active rheumatoid arthritis.